MTOR and breast carcinoma: Our experiments indicated that MEDAG activated the AKT/AMPK/mTOR pathway to enhance proliferation, migration, invasion and EMT, and that an inhibitor or agonist could partially reverse the above progression, suggesting that MEDAG may influence breast cancer by regulating this pathway.